Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
343.45 EUR | +1.34% |
|
+4.90% | +0.47% |
Jan. 17 | Terry Smith's portfolio for 2025 | ![]() |
Jan. 16 | L'Oréal: collaboration with IBM in generative AI | CF |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 29.87B | 27.99B | 32.29B | 38.26B | 41.18B | |||||
Total Revenues | 29.87B | 27.99B | 32.29B | 38.26B | 41.18B | |||||
Cost of Goods Sold, Total | 8.06B | 7.53B | 8.43B | 10.58B | 10.77B | |||||
Gross Profit | 21.81B | 20.46B | 23.85B | 27.68B | 30.42B | |||||
Selling General & Admin Expenses, Total | 15.28B | 14.3B | 16.68B | 19.09B | 20.99B | |||||
R&D Expenses | 985M | 964M | 1.03B | 1.14B | 1.29B | |||||
Other Operating Expenses, Total | 16.26B | 15.26B | 17.7B | 20.23B | 22.27B | |||||
Operating Income | 5.55B | 5.2B | 6.15B | 7.45B | 8.14B | |||||
Interest Expense, Total | -75.4M | -79.2M | -38M | -70.4M | -227M | |||||
Interest And Investment Income | 392M | 392M | 397M | 538M | 583M | |||||
Net Interest Expenses | 316M | 313M | 359M | 468M | 356M | |||||
Income (Loss) On Equity Invest. | 1M | 900K | 600K | 1.4M | 200K | |||||
Other Non Operating Income (Expenses) | -15.9M | -23.2M | -30.1M | -65.8M | -46.6M | |||||
EBT, Excl. Unusual Items | 5.85B | 5.49B | 6.48B | 7.85B | 8.45B | |||||
Restructuring Charges | -120M | -382M | -150M | -58M | -88.5M | |||||
Merger & Related Restructuring Charges | -6.1M | -24M | -14.3M | - | -46M | |||||
Impairment of Goodwill | -59M | -24.6M | -255M | - | -250M | |||||
Gain (Loss) On Sale Of Assets | 14M | -3.5M | -400K | -122M | -6.7M | |||||
Asset Writedown | -83.8M | -65.2M | -82.8M | -39M | -20.6M | |||||
Legal Settlements | -55.8M | - | 45.6M | - | - | |||||
Other Unusual Items | -126M | -210M | 24.2M | -22.5M | -38.1M | |||||
EBT, Incl. Unusual Items | 5.41B | 4.78B | 6.05B | 7.61B | 8B | |||||
Income Tax Expense | 1.66B | 1.21B | 1.45B | 1.9B | 1.81B | |||||
Earnings From Continuing Operations | 3.76B | 3.57B | 4.6B | 5.71B | 6.19B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 3.76B | 3.57B | 4.6B | 5.71B | 6.19B | |||||
Minority Interest | -5.2M | -4.2M | -5.1M | -6M | -6.5M | |||||
Net Income - (IS) | 3.75B | 3.56B | 4.6B | 5.71B | 6.18B | |||||
Net Income to Common Incl Extra Items | 3.75B | 3.56B | 4.6B | 5.71B | 6.18B | |||||
Net Income to Common Excl. Extra Items | 3.75B | 3.56B | 4.6B | 5.71B | 6.18B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6.7 | 6.37 | 8.24 | 10.65 | 11.55 | |||||
Basic EPS - Continuing Operations | 6.7 | 6.37 | 8.24 | 10.65 | 11.55 | |||||
Basic Weighted Average Shares Outstanding | 560M | 559M | 558M | 536M | 535M | |||||
Net EPS - Diluted | 6.66 | 6.34 | 8.21 | 10.61 | 11.52 | |||||
Diluted EPS - Continuing Operations | 6.66 | 6.34 | 8.21 | 10.61 | 11.52 | |||||
Diluted Weighted Average Shares Outstanding | 563M | 562M | 560M | 538M | 537M | |||||
Normalized Basic EPS | 6.52 | 6.13 | 7.25 | 9.15 | 9.85 | |||||
Normalized Diluted EPS | 6.49 | 6.1 | 7.23 | 9.12 | 9.82 | |||||
Dividend Per Share | 3.85 | 4 | 4.8 | 6 | 6.6 | |||||
Payout Ratio | 59.23 | 61.47 | 51.16 | 47.14 | 55.39 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.62B | 6.57B | 6.93B | 8.29B | 9.01B | |||||
EBITA | 5.67B | 5.25B | 6.22B | 7.46B | 8.21B | |||||
EBIT | 5.55B | 5.2B | 6.15B | 7.45B | 8.14B | |||||
Effective Tax Rate - (Ratio) | 30.62 | 25.32 | 23.9 | 24.95 | 22.63 | |||||
Total Current Taxes | 1.7B | 1.22B | 1.36B | 2B | 1.91B | |||||
Total Deferred Taxes | -42.5M | -10.1M | 83.6M | -96.5M | -95.3M | |||||
Normalized Net Income | 3.65B | 3.42B | 4.04B | 4.9B | 5.28B | |||||
Non-Cash Pension Expense | -15.2M | -20.3M | -15.5M | -9.1M | -11.3M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 9.21B | 8.65B | 10.59B | 12.06B | 13.36B | |||||
Selling and Marketing Expenses | 9.21B | 8.65B | 10.59B | 12.06B | 13.36B | |||||
Research And Development Expense From Footnotes | 985M | 964M | 1.03B | 1.14B | 1.29B | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 144M | 130M | 155M | 169M | 168M | |||||
Total Stock-Based Compensation | 144M | 130M | 155M | 169M | 168M |